Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
188Re-HEDP for castration-resistant prostate cancer bone metastases
CTR20181152Phase 2Completed
- Sponsor
- Shanghai Institute of Applied Physics
- Start
- Nov 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Rhenium-188-HEDP in prostate cancer (PCa), sponsored by Shanghai Institute of Applied Physics. Started Nov 2018; status: completed.
02
Drugs
Rhenium-188-HEDP
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20181152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181152.